Population pharmacokinetic-pharmacodynamic (PK-PD) modeling of CPX-351-induced thrombocytopenia

被引：0
|
作者：
Cook, Sarah F. [1 ]
Wang, Qi [2 ]
Mager, Donald E. [1 ]
Van Wart, Scott A. [1 ]
机构：
[1] Enhanced Pharmacodynam LLC, Buffalo, NY USA
[2] Jazz Pharmaceut Inc, Palo Alto, CA USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2018年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
W-025
引用
收藏
页码：S101 / S101
页数：1
相关论文
共 50 条
  • [31] Semi-physiological pharmacokinetic-pharmacodynamic (PK/PD) models for troxacitabine-induced neutropenia and thrombocytopenia
    Ng, C. M.
    Muralidhar, B.
    Takimoto, C. H.
    Lin, C.
    Patnaik, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
    Venisse, Nicolas
    Peytavin, Gilles
    Bouchet, Stephane
    Gagnieu, Marie-Claude
    Garraffo, Rodolphe
    Guilhaumou, Romain
    Solas, Caroline
    ANTIVIRAL RESEARCH, 2020, 181
  • [33] The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics
    Agoram, Balaji M.
    Martin, Steven W.
    van der Graaf, Piet H.
    DRUG DISCOVERY TODAY, 2007, 12 (23-24) : 1018 - 1024
  • [34] A pumpless multi-organ-on-a-chip (MOC) combined with a pharmacokinetic-pharmacodynamic (PK-PD) model
    Lee, Hyuna
    Kim, Dae Shik
    Ha, Sang Keun
    Choi, Inwook
    Lee, Jong Min
    Sung, Jong Hwan
    BIOTECHNOLOGY AND BIOENGINEERING, 2017, 114 (02) : 432 - 443
  • [35] COMBINED PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) MODEL TO PREDICT METHEMOGLOBIN FORMATION BY A NEW CANDIDATE ANTIMALARIAL
    BRUECKNER, RP
    FLECKENSTEIN, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (02) : 156 - 156
  • [36] Population Pharmacokinetic (PK)/Pharmacodynamic (PD) Modeling of Myelosuppression in Patients with Hematologic Malignancies for CPX-351 and Standard-of-Care 7+3 Therapy
    Wang, Qi
    Cook, Sarah F.
    Van Wart, Scott A.
    Mager, Donald E.
    Faderl, Stefan
    BLOOD, 2018, 132
  • [37] Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective
    Wong, Harvey
    Bohnert, Tonika
    Damian-Lordache, Valeriu
    Gibson, Christopher
    Hsu, Cheng-Pang
    Krishnatry, Anu Shilpa
    Liederer, Bianca M.
    Lin, Jing
    Lu, Qiang
    Mettetal, Jerome T.
    Mudra, Daniel R.
    Nijsen, Marjoleen J. M. A.
    Schroeder, Patricia
    Schuck, Edgar
    Suryawanshi, Satyendra
    Trapa, Patrick
    Tsai, Alice
    Wang, Haiqing
    Wus, Fan
    DRUG DISCOVERY TODAY, 2017, 22 (10) : 1447 - 1459
  • [38] The in vivo study on antioxidant activity of wendan decoction in treating hyperlipidemia: a pharmacokinetic-pharmacodynamic (PK-PD) model
    Xu, Nan
    Ijaz, Muhammad
    Shu, Yishuo
    Wang, Peng
    Ma, Lei
    Wang, Ping
    Ding, Hailing
    Shahbaz, Muhammad
    Shi, Haiyan
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [39] The dose regimen formulation of tilmicosin against Lawsonia intracellularis in pigs by pharmacokinetic-pharmacodynamic (PK-PD) model
    Luo, Wanhe
    Qin, Hua
    Chen, Dongmei
    Wu, Mengru
    Meng, Kuiyu
    Zhang, Aoxue
    Pan, Yunahu
    Qu, Wei
    Xie, Shuyu
    MICROBIAL PATHOGENESIS, 2020, 147
  • [40] COMBINED PHARMACOKINETIC PHARMACODYNAMIC (PK/PD) MODELING
    COLBURN, WA
    JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 28 (09): : 769 - 771
12345